Olympus Biotech Corporation is dedicated to the further advancement of orthopedics and regenerative medicine to improve the lives of patients around the world. Olympus Biotech markets and sells OP-1™ Putty and OP-1™ Implant which are currently approved in the
under Humanitarian Device Exemptions (HDEs) for revision posterolateral lumbar spine fusion and for the treatment of long bone U.S.
nonunions, respectively. OP-1 is also approved in
Australia and Canada as OP-1 Implant, and in and the European Union as Osigraft and Opgenra. Approximately 40,000 patients have been treated globally with OP-1 Products. Switzerland
Learn more at http://www.op1.com/